Cargando…

Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study

AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Filipe, Augusto, Pedroso, Pedro, Almeida, Susana, Neves, Rita, Boudreault, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070455/
https://www.ncbi.nlm.nih.gov/pubmed/24756462
http://dx.doi.org/10.1007/s40268-014-0044-x
_version_ 1782322689846804480
author Filipe, Augusto
Pedroso, Pedro
Almeida, Susana
Neves, Rita
Boudreault, Sylvie
author_facet Filipe, Augusto
Pedroso, Pedro
Almeida, Susana
Neves, Rita
Boudreault, Sylvie
author_sort Filipe, Augusto
collection PubMed
description AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequivalence study, under fasting conditions. A single oral dose of ibandronic acid as one 150-mg film-coated tablet was administered in each study period. Each washout period lasted 14 days. Blood samples were collected according to a predefined sampling schedule and up to 48.0 hours after administraton in each period. Plasma concentrations of ibandronic acid were measured using a liquid chromatograph–mass spectrometry/mass spectrometry method. Bioequivalence between generic and reference medicinal products is acceptable if the 90 % confidence intervals (CI) of ratio of least-squares means between the test and the reference product of ln-transformed area under the serum concentration–time curve from time zero to time of last measurable concentration (AUC(0–t)) is within the 80.00–125.00 % interval. Prospectively, a scaled average bioequivalence approach for maximum serum concentration (C (max)) was established. RESULTS: 153 healthy volunteers were enrolled and randomized. After the test formulation (T) and first and second Bonviva(®) (R) dosing, the C (max) was 96.71 ± 90.19 ng/mL, 92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the AUC(0–t) was 390.83 ± 287.27 ng·h/mL, 388.54 ± 356.76 ng·h/mL and 383.53 ± 246.72, respectively. Ratios of T/R and 90 % CI were 100.92 % (94.35–107.94) for AUC(0–t), 100.90 % (94.37–107.88) for AUC(0–inf) and 102.56 % (95.05–110.67) for C (max). CONCLUSIONS: Test formulation of ibandronic acid is bioequivalent in rate and extent of absorption to Bonviva(®) following a 150-mg dose, under fasting conditions.
format Online
Article
Text
id pubmed-4070455
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-40704552014-07-16 Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study Filipe, Augusto Pedroso, Pedro Almeida, Susana Neves, Rita Boudreault, Sylvie Drugs R D Original Research Article AIMS: This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®). METHODS: This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequivalence study, under fasting conditions. A single oral dose of ibandronic acid as one 150-mg film-coated tablet was administered in each study period. Each washout period lasted 14 days. Blood samples were collected according to a predefined sampling schedule and up to 48.0 hours after administraton in each period. Plasma concentrations of ibandronic acid were measured using a liquid chromatograph–mass spectrometry/mass spectrometry method. Bioequivalence between generic and reference medicinal products is acceptable if the 90 % confidence intervals (CI) of ratio of least-squares means between the test and the reference product of ln-transformed area under the serum concentration–time curve from time zero to time of last measurable concentration (AUC(0–t)) is within the 80.00–125.00 % interval. Prospectively, a scaled average bioequivalence approach for maximum serum concentration (C (max)) was established. RESULTS: 153 healthy volunteers were enrolled and randomized. After the test formulation (T) and first and second Bonviva(®) (R) dosing, the C (max) was 96.71 ± 90.19 ng/mL, 92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the AUC(0–t) was 390.83 ± 287.27 ng·h/mL, 388.54 ± 356.76 ng·h/mL and 383.53 ± 246.72, respectively. Ratios of T/R and 90 % CI were 100.92 % (94.35–107.94) for AUC(0–t), 100.90 % (94.37–107.88) for AUC(0–inf) and 102.56 % (95.05–110.67) for C (max). CONCLUSIONS: Test formulation of ibandronic acid is bioequivalent in rate and extent of absorption to Bonviva(®) following a 150-mg dose, under fasting conditions. Springer International Publishing 2014-04-23 2014-06 /pmc/articles/PMC4070455/ /pubmed/24756462 http://dx.doi.org/10.1007/s40268-014-0044-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research Article
Filipe, Augusto
Pedroso, Pedro
Almeida, Susana
Neves, Rita
Boudreault, Sylvie
Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title_full Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title_fullStr Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title_full_unstemmed Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title_short Bioequivalence Study of Two Formulations of Ibandronic Acid 150-mg Film-Coated Tablets in Healthy Volunteers Under Fasting Conditions: A Randomized, Open-Label, Three-Way, Reference-Replicated Crossover Study
title_sort bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070455/
https://www.ncbi.nlm.nih.gov/pubmed/24756462
http://dx.doi.org/10.1007/s40268-014-0044-x
work_keys_str_mv AT filipeaugusto bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy
AT pedrosopedro bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy
AT almeidasusana bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy
AT nevesrita bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy
AT boudreaultsylvie bioequivalencestudyoftwoformulationsofibandronicacid150mgfilmcoatedtabletsinhealthyvolunteersunderfastingconditionsarandomizedopenlabelthreewayreferencereplicatedcrossoverstudy